T-Cure Bioscience
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Goddard, Irvine, California, 92618, Un...Website
www.t-cure.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About T-Cure Bioscience
T Cure Bioscience is dedicated to providing effective and long-lasting cell therapies for cancer treatment. The company is focused on developing advanced clinical-stage T cell receptor (TCR) therapies aimed at targeting and eliminating solid tumors. Their innovative approach leverages the iSORT platform to enhance therapeutic outcomes. T Cure Bioscience primarily serves patients suffering from cancer, seeking to improve their treatment options.Explore more
T-Cure Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is T-Cure Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at T-Cure Bioscience
Check out if T-Cure Bioscience is spiking on competitors!
Click to see if T-Cure Bioscience had a recent Job posting/layoffs
Check if T-Cure Bioscience has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on T-Cure Bioscience recently announced quarterly report
Funding: Get notified immidiatlly once T-Cure Bioscience has new funding data
Product Launch: Get notified when T-Cure Bioscience launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
T-Cure Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to T-Cure Bioscience
Compare insights from companies similar to T-Cure Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
T-Cure Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
T-Cure Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about T-Cure Bioscience.
T-Cure Bioscience Tech Stack
A closer look at the technologies used by T-Cure Bioscience
T-Cure Bioscience News & Media
T-Cure Bioscience Announces U.S. FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T Against Multiple Solid Tumors
LOS ANGELES--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor therapy (TCR-T) products for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I clinical study evaluating a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervicT-Cure Bioscience Enters Into Agreement With Rutgers to Conduct Clinical Research of Novel T Cell Receptor Therapy for Treatment of Variety of Cancers
SHERMAN OAKS, Calif.--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical study testing a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, luT-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
SHERMAN OAKS, Calif.--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held clinical-stage immuno-oncology company developing the next generation of T cell receptor (TCR) therapies for patients with solid tumors, and Immunotech Biopharm Ltd ("Immunotech"), a leading cellular immunotherapy biopharmaceutical company focused on the research, development, and commercialization of T cell immunotherapies (HKEX: 6978), today announced that they have entered into a license agreement for the researT-Cure Bioscience Announces Expansion of Collaboration With the National Institutes of Health for T Cell Receptor (TCR) Therapy Targeting HERV-E for the Treatment of Kidney Cancer
SHERMAN OAKS, Calif.--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has extended its ongoing research collaboration with the National Heart Lung and Blood Institute (NHLBI), through a formal Collaborative Research and Development Agreement (CRADA) to advance the Company’s HERV-E targeting TCR therapy for renal cell cancer. Additionally,
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding T-Cure Bioscience
Sign Up For FreeTo access detailed company insights
T Cure Bioscience is dedicated to providing effective and long-lasting cell therapies for cancer treatment. The company is focused on developing advanced clinical-stage T cell receptor (TCR) therapies aimed at targeting and eliminating solid tumors. Their innovative approach leverages the iSORT platform to enhance therapeutic outcomes. T Cure Biosc... Read More
